Previous close | 124.02 |
Open | 122.92 |
Bid | 122.90 x 1200 |
Ask | 123.13 x 800 |
Day's range | 121.29 - 123.77 |
52-week range | 75.56 - 138.28 |
Volume | |
Avg. volume | 4,903,335 |
Market cap | 548.932B |
Beta (5Y monthly) | 0.19 |
PE ratio (TTM) | 46.09 |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | 1.37 (1.06%) |
Ex-dividend date | 22 Mar 2024 |
1y target est | N/A |
Bagsværd, Denmark, 3 May 2024 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse. The company’s board members, executives and their associated persons have reported the transactions to Novo Nordisk and have given Novo Nordisk power of attorney on their behalf to publish trading in Novo Nordisk shares by the
Bagsværd, Denmark, 2 May 2024 - financial report for the period 1 January 2024 to 31 March 2024 Operating profit increased by 27% in Danish kroner and by 30% at constant exchange rates (CER) to DKK 31.8 billion. Sales in North America Operations increased by 34% in Danish kroner (35% at CER). Sales growth in the US was positively impacted by gross-to-net sales adjustments related to prior years. Sales in International Operations increased by 8% in Danish kroner (11% at CER).Sales within Diabetes
Bagsværd, Denmark, 1 May 2024 – On 6 February 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 20 billion to be executed during a 12-month period beginning 6 February 2024. Under the programme init